Navigate Fool.com
Will ARNA beat
the market?
Community Rating: 3 Stars: Appealing

6.18 -0.12 (-1.90%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $6.27
Previous Close $6.30
Daily Range $6.16 - $6.33
52-Week Range $4.05 - $9.25
Market Cap $1.4B
P/E Ratio -70.00
Dividend (Yield) $0.00 (0.0%)
Volume 3,706,475
Average Daily Volume 5,429,964
Current FY EPS -$0.43

How do you think ARNA
will perform against the market?

Top ARNA Bull/Bear Pitches


weightlossman (0)
Submitted August 31, 2010

Arena Pharma's (ARNA) Lorcaserin will eventually be approved. It's side effects are benign. Research has shown that it does not cause pulmonary hypertension nor heart-valve damage. Arena has comple … More

1 Replies Reply Report this Post

DarthMaul09 (< 20)
Submitted July 23, 2010

Even if a new med is found to be clinically useful and has made it past the FDA, then it needs to get past insurance companies and be marketed adequately to physicians, who still remember Fen/Fen and … More

7 Replies Reply Report this Post

News & Commentary Rss Feed

Biotech Tweet of the Week: Love Being Private

Investors often ignore private biotechs because they can't buy shares, but investors in companies such as InterMune and the obesity drug makers -- Arena Pharmaceuticals, VIVUS, and Orexigen -- need to follow their privately-held competitors.

XBI, MNKD, UTHR, ARNA: Large Inflows Detected at ETF

ARNA Crosses Below Key Moving Average Level

Interesting ARNA Put And Call Options For May 30th

Interesting ARNA Put And Call Options For May 23rd

Morning Movers in Biotech: Medicines Co., Omeros Corporation, Opko Health, Inc. and VIVUS, Inc.

Today's top stories in health care and biotech.

MannKind's Dominating Win Annihilates the Shorts

One of the biggest winners on the entire market today sends the short sellers packing.

MannKind Doubles on FDA News, Could Drive Short Covering in Biotech Sector

After a big slump, biotech is having a great week.

Can Arena and VIVUS Profit From Glaxo's Troubles?

GlaxoSmithKline had to recall its obesity drug alli, but it isn't clear if Arena Pharmaceuticals and VIVUS will be able to benefit.

Why GlaxoSmithKline PLC Shrugged Off Alli's Recall

GlaxoSmithKline issued a voluntary recall for its OTC weight-loss pill Alli last week. Will this recall have a material impact on GlaxoSmithKline's business?

See More ARNA News...





Arena Pharmaceuticals, Inc. (ARNA) Description

A clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Website: http://www.arenapharm.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks